Teladoc Health, Inc. reported that its Integrated Care segment generated $394.3 million in revenue and $65.2 million in adjusted EBITDA for the second quarter of 2023. In contrast, its BetterHelp segment provided only $0.5 million in adjusted EBITDA. The consolidated adjusted EBITDA for Teladoc was $65.7 million, underscoring Integrated Care’s role as the main profit driver.
Integrated Care’s success is attributed to enterprise contracts and growth opportunities in chronic care bundles, contrasting with BetterHelp’s challenges related to insurance shifts and provider availability. The company plans to launch Teladoc One in January 2027, aiming to unify primary and chronic care services, potentially positioning Integrated Care as the company’s primary earnings generator.
Shares of Teladoc (TDOC) have increased by 18.5% over the past six months, outperforming the industry’s 8.1% gain. Currently, TDOC is valued at a forward price-to-sales ratio of 0.47x, below the industry average of 0.53x. The Zacks Consensus Estimate for TDOC’s 2026 loss is projected at 89 cents per share, reflecting a 21.9% increase from the previous year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
